Stockscreener 앱 받기
11.01
1.52%
-0.17
시간 외 거래:
11.01
전일 마감가:
$11.18
열려 있는:
$11.15
하루 거래량:
450.32K
Relative Volume:
1.21
시가총액:
$352.03M
수익:
$2.07M
순이익/손실:
$-47.68M
주가수익비율:
-3.3364
EPS:
-3.3
순현금흐름:
$-31.31M
1주 성능:
-9.08%
1개월 성능:
+14.33%
6개월 성능:
+35.42%
1년 성능:
+212.78%
1일 변동 폭
$10.84
$11.28
1주일 범위
$10.75
$13.30
52주 변동 폭
$3.4301
$13.30
Delcath Systems Inc Stock (DCTH) Company Profile
명칭
Delcath Systems Inc
전화
(518) 743-8892
주소
566 QUEENSBURY AVENUE, QUEENSBURY, NY
DCTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.01 | 352.03M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Craig Hallum | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2022-07-26 | 재개 | Canaccord Genuity | Buy |
| 2021-12-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Canaccord Genuity | Buy |
| 2021-01-05 | 개시 | BTIG Research | Buy |
| 2020-06-01 | 개시 | Laidlaw | Buy |
모두보기
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet? - Simply Wall St
Where are the Opportunities in (DCTH) - Stock Traders Daily
Delcath Systems stock soars to 52-week high of $12.99 - Investing.com
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting - Marketscreener.com
Clear Street initiates Buy on Delcath Systems stock, highlights profitability potential - Investing.com
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Uveal melanoma Treatment Market: Segmentation Trends, - openPR
When (DCTH) Moves Investors should Listen - Stock Traders Daily
Polar Asset Management Partners Inc. Purchases New Position in Delcath Systems, Inc. (NASDAQ:DCTH) - MarketBeat
Delcath to trial Hepzato drug device combo in colorectal cancer - Yahoo Finance
FDA finishes review of Delcath’s IND application of HEPZATO combo trial - TipRanks
Delcath Secures FDA Clearance for Phase 2 Trial of HEPZATO in Colorectal Cancer - StockTitan
Delcath Systems (NASDAQ:DCTH) jumps 13% this week, taking one-year gains to 330% - Yahoo Finance
Delcath Systems Inc (DCTH) Shares Up 5.61% on Nov 29 - GuruFocus.com
Delcath Systems (NASDAQ:DCTH) spikes 17% this week, taking one-year gains to 301% - Simply Wall St
Objective long/short (DCTH) Report - Stock Traders Daily
DCTH (Delcath Systems) 3-Year FCF Growth Rate : 38.20% (As of Sep. 2024) - GuruFocus.com
Principal Financial Group Inc. Makes New $808,000 Investment in Delcath Systems, Inc. (NASDAQ:DCTH) - MarketBeat
89,447 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Bought by Principal Financial Group Inc. - Defense World
Delcath Systems Reports Strong Q3 Growth and Expansion - MSN
Delcath Begins Platform Expansion With Two Phase 2 Trials (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (DCTH) Reports Q3 Loss - MSN
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth (NASDAQ:DCTH) - Seeking Alpha
(DCTH) Investment Analysis - Stock Traders Daily
Delcath Systems Stock (NASDAQ:DCTH) Among the Best Multibagger Stock to Buy Heading into 2025 - Insider Monkey
Rosalind Advisors, Inc. Increases Stake in Delcath Systems Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Intrahepatic Cholangiocarcinoma Treatment Market size is expected to grow owing to the launch of emerging therapies by 2034, estimates DelveInsight - Barchart
FY2024 EPS Estimate for Delcath Systems Raised by Analyst - MarketBeat
HC Wainwright Forecasts Weaker Earnings for Delcath Systems - MarketBeat
Uveal melanoma Treatment Market Countermeasures Of Economic - openPR
HC Wainwright Reiterates Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems revenue hits USD 11.2M in Q3 2024, a 44% increase - Medical Buyer
Delcath Systems Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Delcath Systems stock soars to 52-week high of $12 amid robust gains - Investing.com Australia
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Delcath Systems, Inc. (NASDAQ:DCTH) Q3 2024 Earnings Call Transcript - Insider Monkey
Delcath Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade - MSN
Delcath Systems Inc (DCTH) Q3 2024 Earnings: Revenue Surpasses E - GuruFocus.com
Delcath Systems Revenue Surges 44% to $11.2M as HEPZATO Launch Gains Momentum | DCTH Stock News - StockTitan
Uncovering Potential: Delcath Systems's Earnings Preview - Benzinga
(DCTH) Investment Analysis and Advice - Stock Traders Daily
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
Delcath Systems to Participate in Upcoming Investor Conferences - StockTitan
Delcath Systems Inc (DCTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Delcath Systems Inc 주식 (DCTH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Aharon Gil | Director |
Mar 19 '24 |
Buy |
3.72 |
26,882 |
100,001 |
1,069,710 |
| SALAMON STEVEN A J | Director |
Mar 19 '24 |
Buy |
3.72 |
26,882 |
100,001 |
1,121,025 |
1.54%
자본화:
|
볼륨(24시간):